Abstract Categories 

Abstract DatesAbstract Reference GuideQuick Reference Guide

Category Types

Primary Category and Subcategory

All abstract submitters will be asked to indicate the primary category and subcategory with which the abstract most closely aligns. This primary selection will aid the abstract reviewers in placing the abstract into the most appropriate session, if accepted for oral presentation. Accepted abstracts are also listed according to the primary category and subcategory selected within the JITC supplement and the Poster Hall.

Secondary Categories

Should the submitter believe more than one category is applicable, they can select a secondary category and subcategory. The secondary category and subcategory will only be used to aid the abstract reviewers in placing the abstract into the most appropriate session, if accepted for oral presentation. The secondary category and subcategory WILL NOT be used for the abstract listing in publications or placement in the Poster Hall.

Abstract Categories and Subcategories

Clinical Trial Abstract Categories

  1. Skin Cancers
  2. Lung Cancers
  3. Genitourinary Cancers
  4. Breast Cancers
  5. Gynecologic Cancers
  6. Hematologic Malignancies
  7. Brain and CNS Cancers
  8. Head and Neck Cancers
  9. Gastrointestinal/GEJ/Colorectal Cancers
  10. Hepatocellular Cancer
  11. Multi-Cancer
  12. Biomarker-Defined Cancers
  13. Other
  1. Skin Cancers
  2. Lung Cancers
  3. Genitourinary Cancers
  4. Breast Cancers
  5. Gynecologic Cancers
  6. Hematologic Malignancies
  7. Brain and CNS Cancers
  8. Head and Neck Cancers
  9. Gastrointestinal/GEJ/Colorectal Cancers
  10. Hepatocellular Cancer
  11. Multi-Cancer
  12. Biomarker-Defined Cancers
  13. Other

Non-Clinical Trial Abstract Categories

  1. Imaging
  2. Next-Generation Sequencing
  3. Neoantigen Identification and Characterization
  4. Non-canonical/Dark Genome coded antigens
  5. Animal Models
  6. Circulating DNA and Other Blood-Based Soluble Markers
  7. Gene Editing
  8. Bioengineering
  9. Other
  1. Chimeric Antigen Receptors
  2. Non-CAR Adoptive Cell Therapies
  3. Other Cellular Therapies
  4. Response/Resistance Mechanisms
  5. Combinations
  6. Toxicity
  7. TILs
  8. Other
  1. Response/Resistance Mechanisms
  2. Autoimmunity/Toxicity
  3. Innate Immune Checkpoints
  4. Combination Treatments (Other Immunotherapies)
  5. Combination Treatments (Chemotherapy, Radiotherapy, Targeted Therapy)
  6. Other
  1. Vaccines
  2. Cytokines
  3. Oncolytic Viruses
  4. TLR Agonists
  5. STING Agonists
  6. Intra-Tumoral Agents
  7. Immune Effects of Non-Immunotherapeutic Treatments
  8. Reponses/Resistance Mechanisms
  9. Toxicity
  10. Other
  1. Antibody-Drug Conjugates
  2. Antibody-Radionuclide Conjugates
  3. Bispecific Molecules
  4. Response/Resistance Mechanisms
  5. Combination Treatments
  6. Toxicity
  7. Other
  1. Toxicity Management: Clinical Care and Best Practices
  2. Mechanisms of Toxicities
  3. Long-Term Immunotherapy Toxicities
  4. Neural Toxicities
  5. Other
  1. Immunotherapeutic Response/Resistance Mechanisms
  2. Diet, Exercise and Metabolism
  3. Gut Microbiome
  4. Tumor Microbiome
  5. Aging
  6. Gender
  7. Other
  1. Immunotherapy Cost and Value Analyses
  2. Patient Access Initiatives
  3. Regulatory Considerations
  4. Reimbursement Initiatives
  5. Immunotherapy Clinical Trial Design
  6. Patient Exclusion/Inclusion Criteria
  7. Other
  1. Cellular Metabolism
  2. Oncogenetics
  3. Epigenetic Regulation
  4. Tumor Antigens and Others
  5. Virus-Driven Cancers
  6. Cancer-Associated Fibroblasts
  7. Endothelial Cells
  8. Tumor Microenvironment
  9. Mouse Models
  10. Neuro-oncology
  11. Toxicity
  12. Senescence
  13. Other

Enrollment Report Data Table

Clinical trial abstract submitters are asked to complete the Enrollment Report data table, which follows the NIH data template. This data will not be shared with abstract reviewers and will not be included in the publication of accepted abstracts. The data will only be accessible to SITC staff and will only be reported in aggregate. Presenters for abstracts that are accepted for a poster or oral presentation are encouraged to include this data in the presentation if applicable.